effect of colchicine on mmp-9, nox2, and tgf-β1 in myocardial infarct

Conditions: ST Elevation Myocardial Infarction; Colchicine; Cardiac Remodeling, Ventricular

Summary: reducing nox-2, mmp-9, and tgf-β1 expression in preventing ventricular remodelling post acute st-segment elevation myocardial infarction using colchicine (post late reperfusion percutaneous coronary intervention and non-reperfusion and in vitro study on ischemic rat cardiomyocyte culture model). coronary heart disease (chd) is the most common cause of mortality and disability worldwide. the handling of reperfusion in indonesia is still far below the required standard. most stemi patients in indonesia arrive late to a health facility with symptoms that have been present for more than 12 hours (late-onset). heart failure following a myocardial infarction is one of the long-term complications of stemi. patients with stemu who do not receive reperfusion were more likely to develop this consequence. according to several studies, microtubules in cardiomyocytes have been identified as an essential regulator of cardiomyocytes' ability to respond to shear stress, which offers compression resistance and facilitates mitochondrial energy production. microtubule densification, which occurs due to remodelling in heart failure, disrupts the microtubule network. the role of reactive oxygen species (ros) produced by ischemic myocardium in this remodelling is thus inextricably linked. nadph oxidase is one of the enzymes involved (nox). nox-2 levels have been reported to be higher in myocardial infarction and cardiac remodelling, and it has a close interaction with microtubule network, with damage of microtubule tissue increasing nox-2 generation of reactive oxygen species. by eroding the ecm and triggering cytokines and chemokines to recruit inflammatory cells to eliminate necrotic cardiomyocytes, matrix metalloproteinase 9 (mmp-9) aids tissue rebuilding. induction and activation of endogenous tgf-signaling pathways after myocardial infarction have also been discovered to play a function. tgf-β may play a role in the resolution of the inflammatory response in the early stages of infarct repair by inactivating macrophages and decreasing endothelial cell chemokine and cytokine production. tgf-β stimulates the fibrogenic pathway by causing extracellular matrix deposition and fibrosis later. colchicine is a commonly prescribed anti-inflammatory medication with a low cost. the mechanism of colchicine is tubulin binding, which prevents microtubule assembly and polymerization. colchicine inhibits microtubule development at low concentrations and promotes microtubule depolymerization at higher concentrations. several studies have demonstrated that low-dose colchicine can help reduce severe cardiac outcomes such as cardiovascular mortality, stroke, and cardiac arrest following myocardial infarction. colchicine is known to cause partial restoration of microtubule tissue in the perinuclear region. colchicine has also been shown in earlier research to reduce the expression of mmp-9, nox2, and tgf-β this study aims to evaluate whether colchicine could prevent ventricular remodelling in stemi patients with delayed reperfusion and non reperfusion. the minor hypothesis of this study was colchicine can lower nox-2, mmp-9, and tgf-β expression in the clinical situation of patients with delayed and non-reperfusion stemi following pci. randomization with 1:1 allocation were used to classify the patients, each group include 41 patients with one group receiving colchicine therapy and standard therapy and the other receiving standard therapy only. colchicine administration was the independent variable. stemi patients with delayed and non-reperfusion ikp who met the inclusion criteria are included in this randomized clinical trial. left ventricular end-diastolic volume (lvedv) was the dependent variable while serum mmp-9, nox-2, and tgf-β were the intermediate variables. in the treatment group, colchicine 1 mg is administered before pci or admission to the iccu, and colchicine is continued at 0.5 mg/day for a month. within 24 to 36 hours of treatment initiation, the patient had echocardiography, nox-2, mmp-9, and tgf-β levels evaluated. on days 4-5, a second nox-2, mmp-9, and tgf-β screening were performed. the follow up two months after treatment initiation includes an assessment of drug compliance, symptoms, and echocardiography. depending on the normality of the data distribution, the difference between groups is performed using the unpaired t-test or the mann-whitney test. the significant difference between the treatment groups is indicated by a p-value of 0.05.


Eligibility criteria:
inclusion criteria: * subjects who presenting with stemi more than 12 hours from the onset of chest pain * aged 40-70 years * agreed with the informed consent exclusion criteria: * aged \ 70 years * subjects that have unstable condition such as comorbid disease (infection, inflammation, malignancy, severe renal failure (egfr \<30), a history of hepatic cirrhosis, acute exacerbation of hepatitis, or severe liver disease, alcoholic patient, cardiac arrest, ventricular fibrillation or cardiogenic shock, unstable hemodynamic) * subjects that have colchicine hypersensitivity * pregnancy or breastfeed

Keywords: stemi colchicine mmp-9 nox2 tgf-beta 1